 |
Vol.58 No.4 contents | Japanese/English |
 | Full Text of PDF (226K) Article in Japanese |
- Invited Review Article -
The Treatment Strategy for ALK-positive Non-small-cell Lung Carcinoma
Ryo Toyozawa1, Kaname Nosaki1, Takashi Seto11Department of Thoracic Oncology, National Kyushu Cancer Center, Japan
ALK-positive lung cancer accounts for approximately 4% of all lung cancer. Tyrosine kinase inhibitors targeting the ALK domain (ALK-TKI) are being rapidly developed. We can use crizotinib as a 1st generation ALK-TKI, and alectinib and ceritinib as 2nd generation ALK-TKIs. Third generation ALK-TKIs (lorlatinib and brigatinib) are also expected to have therapeutic effects. We mainly discuss these ALK-TKIs based on the results of study, and we explain the position of ALK-TKIs in the practice guidelines for lung cancer, as well as the methods for choosing the 1st and 2nd line drugs.
key words: ALK-positive lung carcinoma, Crizotinib resistant, Alectinib, Lorlatinib, Brigatinib
JJLC 58 (4): 258-261, 2018
